Keywords: Singapore; cancer; guideline; haematology; multiple myeloma.

Plain language summary

Multiple myeloma (MM) is the second most common haematologic malignancy and remains incurable. Significant advances have been made in both supportive care and definitive therapy for MM, leading to marked improvements in survival and quality of life. The availability of potent novel agent-based induction regimens, as well as methods to assess deeper levels of response, has transformed the landscape of MM therapy. Balancing therapeutic efficacy against toxicities and cost-effectiveness remains a key challenge to be addressed. Here, the Singapore myeloma study group provides consensus recommendations on the management of newly diagnosed MM, incorporating key developments in diagnostics, response assessment, supportive care and definitive therapy.